Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy
- 28 February 2012
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 158 (1), 171-179
- https://doi.org/10.1016/j.jconrel.2011.09.097
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patientsBritish Journal of Cancer, 2010
- Pegylated arginase I: a potential therapeutic approach in T-ALLBlood, 2010
- Replacing Mn2+ with Co2+ in Human Arginase I Enhances Cytotoxicity toward l-Arginine Auxotrophic Cancer Cell LinesACS Chemical Biology, 2010
- Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)Cancer Cell International, 2009
- Enhanced Hepatocyte Growth Factor Signaling by Type II Transforming Growth Factor-β Receptor Knockout Fibroblasts Promotes Mammary TumorigenesisCancer Research, 2007
- Pegylated arginine deiminase: a novel anticancer enzyme agentExpert Opinion on Investigational Drugs, 2006
- Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminaseCancer Letters, 2006
- Insights into the interaction of human arginase II with substrate and manganese ions by site‐directed mutagenesis and kinetic studiesThe FEBS Journal, 2005
- Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinomaCancer Letters, 2005
- The Reversible Inactivation of Rat‐Liver Arginase at Low pHJBIC Journal of Biological Inorganic Chemistry, 1972